Aim To observe the effects of high-loading-dose trimetazidine on serum growth differentiation factor-15(GDF-15), monocyte chemoattractant protein-1(MCP-1), and high sensitive C-reactive protein(hs-CRP) level in patients with coronary heart disease underwent percutaneous coronary intervention(PCI). To evaluate the beneficial effects of high-loading-dose of trimetazidine before PCI in patients with coronary heart disease. Methods Totally 96 consecutive patients with coronary heart disease were divided into trimetazidine group(56 cases) and control group(40 cases). Standard medical therapies were given in all patients. In trimetazidine group, patients were given high-loading-dose of trimetazidine(60 mg) 30 minutes before PCI and maintenance dose at least 1 month after PCI. The GDF-15, MCP-1, and hs-CRP were measured in all enrolled subjects 24-hour after PCI. The net adverse clinical events(NACE) and major adverse cardiovascular cerebral events(MACCE) during the follow-up period were observed. Results The serum GDF-15 levels in trimetazidine group were lower than control group (737.24±299.85 ng/L vs 1175.84±523.52 ng/L, P=0.002). The MCP-1 and hs-CRP levels between the two groups had no statistical difference. Incidence of NACE in trimetazidine group were lower than control group(P=0.012), with statistical difference. Conclusions High-loading-dose of trimetazidine before PCI reduces GDF-15 level and incidence of NACE. GDF-15 is independent risk factor for prognosis of coronary heart disease.